Clinton Maynard toalks to Rebekah Cassidy from Ausbiotech about the proposed 15-year cap on the R&D Tax Incentive ignores the lengthy clinical trial timelines needed for complex diseases like cancer and dementia, threatening to drive vital research, manufacturing, and investment offshore.